BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 31, 2026
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Feb. 20, 2002
View Archived Issues
Microscience Completes £25.5M Round, Plans Clinical Programs
LONDON - Microscience Ltd. raised £25.5 million (US$36.3 million) in a third-round funding, enabling it to put five infectious disease vaccines into clinical trials this year and develop them through to Phase IIb. (BioWorld International)
Read More
Hungarian Firm ComGenex Adds Discovery To Chemistry Services
Read More
Common Gene Links Immune System’s Generation Of Diversity
Read More
British Biotech Gains License To Cancer Drug In Phase II
Read More
Alizyme Receives Approval For Phase III Trial Of Colal-Pred
Read More
LION Streamlining Operations, Eliminating About 80 Positions
Read More
EU Commissioner Continues Push For Changes In Policy
Read More
HiberGen Raises EUR3.8M In Follow-On Funding From Trinity
Read More
Other News To Note
Read More
Oxagen, Insmed Enter Alliance On Polycystic Ovary Syndrome
Read More
Arrow Raises £7M In Second Round For Anti-Infectives Work
Read More
Australian Researchers Isolate Gene Implicated In Hay Fever
Read More
Sanofi-Synthélabo Selects Melanoma Vaccine From IDM
Read More
